Article
Advanced RCC benefits from multimodal approach
Patients with metastatic renal cell cancer historically have had a poorprognosis, and attempts with hormonal therapy and chemotherapy have haddisappointing results. In this exclusive Urology Times interview, W. MarstonLinehan, MD, discusses new treatment strategies for renal cell carcinoma,including multimodality therapy with surgery and systemic therapy, and adoptiveimmunotherapy. Dr. Linehan is chief of urologic surgery at the NationalCancer Institute, Bethesda, MD. UT Editorial Consultant Andrew C. Novick,MD, chairman of the Cleveland Clinic Urological Institute, conducted theinterview.
Related Videos
Study results affirm effectiveness of evolving prostate cancer therapies
Non–Muscle Invasive-Bladder Cancer Overview
Laura Davis, MD, on link between microplastics and bladder cancer
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up
BRCA Mutations in mHSPC: Impact on Therapy Selection
Formulations, Food, and Frequency: Optimizing Absorption and Tolerability in Daily Practice
Defining and Managing BCG-Unresponsive NMIBC
Considerations for patient follow-up after onabotA administration
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Related Content
